Literature DB >> 31980142

Coronary Artery Calcification, Statin Use and Long-Term Risk of Atherosclerotic Cardiovascular Disease Events (from the Multi-Ethnic Study of Atherosclerosis).

Mahmoud Al Rifai1, Michael J Blaha2, Jaideep Patel3, Jia Xiaoming1, Miguel Cainzos-Achirica4, Philip Greenland5, Matthew Budoff6, Joseph Yeboah7, Khurram Nasir8, Mouaz H Al-Mallah8, Salim S Virani9.   

Abstract

The prognostic utility of coronary artery calcium (CAC) for individuals taking statins is unclear. We hypothesized that CAC remains associated with atherosclerotic cardiovascular disease (ASCVD) events in individuals using statins at baseline or among those started on statin at follow-up. The Multi-Ethnic Study of Atherosclerosis is a prospective cohort study of 6,814 participants who were enrolled between 2000 and 2002 and were free of clinical ASCVD at baseline. Four follow-up visits were conducted in 2002 to 2004, 2004 to 2006, 2005 to 2007, and 2010 to 2012. CAC was assessed at baseline and follow-up using either an electron-beam CT scanner or a multidetector CT system. Statin use at baseline and follow up was self-reported. Among 6,811 participants with complete information on statin use, mean age was 62 (SD = 10) years, 53% were women, 38% white, 12% Chinese-American, 28% African American, and 22% Hispanic. In multivariable analyses, CAC >0 was associated with a significantly higher risk of ASCVD events regardless of baseline or incident statin use. For example, hazard ratios (95% confidence interval) for the association between CAC >0 and ASCVD were 2.46 (1.41, 4.28) for baseline statin users, 2.08 (1.68, 2.57) for baseline-statin nonusers, and 2.21 (1.56, 3.15) for those started on a statin at follow-up. In conclusion, current statin use does not weaken the prognostic utility of CAC. CAC is associated with incident ASCVD regardless of baseline or incident statin use. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31980142     DOI: 10.1016/j.amjcard.2019.12.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Comparison of cardiac CT angiography coronary artery dimensions and ethnicity in Trinidad: the CADET pilot study.

Authors:  Tonya Welch; Fidel Rampersad; Shastri Motilal; Naveen Anand Seecheran
Journal:  Open Heart       Date:  2022-03

2.  The number of circulating CD34-positive cells is an independent predictor of coronary artery calcification progression: Sub-analysis of a prospective multicenter study.

Authors:  Keishi Ichikawa; Toru Miyoshi; Kazuhiro Osawa; Takashi Miki; Kunihisa Kohno; Kazufumi Nakamura; Yasushi Koyama; Hiroshi Ito
Journal:  Cardiol J       Date:  2021-11-17       Impact factor: 3.487

3.  Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study.

Authors:  Miguel Cainzos-Achirica; Renato Quispe; Reed Mszar; Ramzi Dudum; Mahmoud Al Rifai; Raimund Erbel; Andreas Stang; Karl-Heinz Jöckel; Nils Lehmann; Sara Schramm; Börge Schmidt; Peter P Toth; Jamal S Rana; Joao A C Lima; Henrique Doria de Vasconcellos; Donald Lloyd-Jones; Parag H Joshi; Colby Ayers; Amit Khera; Michael J Blaha; Philip Greenland; Khurram Nasir
Journal:  J Am Heart Assoc       Date:  2022-08-09       Impact factor: 6.106

4.  3-Arylcoumarin inhibits vascular calcification by inhibiting the generation of AGEs and anti-oxidative stress.

Authors:  YuFei Li; Yinbo Pan; Liying Wang; Xiaojing Wang; Haiping Chu; Yan Li; Yanling Mu; Jie Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Calciprotein Particles: Balancing Mineral Homeostasis and Vascular Pathology.

Authors:  Anton G Kutikhin; Lian Feenstra; Alexander E Kostyunin; Arseniy E Yuzhalin; Jan-Luuk Hillebrands; Guido Krenning
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-11       Impact factor: 8.311

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.